The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identification of genetic markers associated with ibrutinib-related cardiovascular toxicity.
 
Issam Hamadeh
No Relationships to Disclose
 
Ryan Jacobs
Consulting or Advisory Role - Adaptive Biotechnologies; AstraZeneca; Genentech; Secura Bio
Speakers' Bureau - Abbvie; AstraZeneca; Janssen; Pharmacyclics
Research Funding - Pharmacyclics; TG Therapeutics
 
Bei Hu
Consulting or Advisory Role - Bayer; Cellectar; Kite, a Gilead company
Research Funding - BeiGene (Inst); Genentech (Inst)
 
Tamara Kay Moyo
No Relationships to Disclose
 
Amy Soni
No Relationships to Disclose
 
Steven I. Park
No Relationships to Disclose
 
Jai Narendra Patel
Honoraria - Janssen Research & Development
Consulting or Advisory Role - Janssen Research & Development; VieCure
Research Funding - Janssen Research & Development (Inst); Professional Compounding Centers of America (Inst); TG Therapeutics (Inst)
 
Nury Steuerwald
No Relationships to Disclose
 
Nilanjan Ghosh
Consulting or Advisory Role - Adaptive Biotechnologies; AstraZeneca; Beigene; Bristol-Myers Squibb; Genmab; Gilead Sciences; Karyopharm Therapeutics; Pharmacyclics/Janssen; Seagen; TG Therapeutics; Verastem
Speakers' Bureau - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Epizyme; Janssen Oncology; Kite/Gilead; Pharmacyclics/Janssen; Seagen
Research Funding - Forty Seven (Inst); Genentech/Roche (Inst); Juno Therapeutics (Inst); Pharmacyclics (Inst); Seagen (Inst); TG Therapeutics (Inst)